|
1
|
Picci P, Mercuri M, Ferrari S, Alberghini
M, Briccoli A, Ferrari C, Pignotti E and Bacci G: Survival in
high-grade osteosarcoma: improvement over 21 years at a single
institution. Ann Oncol. 21:1366–1373. 2010.PubMed/NCBI
|
|
2
|
Hattinger CM, Pasello M, Ferrari S, Picci
P and Serra M: Emerging drugs for high-grade osteosarcoma. Expert
Opin Emerg Drugs. 15:615–634. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Liotta LA and Petricoin E: Cancer
biomarkers: closer to delivering on their promise. Cancer Cell.
20:279–280. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stumvoll M, Nurjhan N, Perriello G, Dailey
G and Gerich JE: Metabolic effects of metformin in
non-insulin-dependent diabetes mellitus. N Engl J Med. 333:550–554.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhou G, Myers R, Li Y, Chen Y, Shen X,
Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N,
Hirshman MF, Goodyear LJ and Moller DE: Role of AMP-activated
protein kinase in mechanism of metformin action. J Clin Invest.
108:1167–1174. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Evans JM, Donnelly LA, Emslie-Smith AM,
Alessi DR and Morris AD: Metformin and reduced risk of cancer in
diabetic patients. BMJ. 330:1304–1305. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bowker SL, Majumdar SR, Veugelers P and
Johnson JA: Increased cancer related mortality for patients with
type 2 diabetes who use sulfonylureas or insulin. Diabetes Care.
29:254–258. 2006. View Article : Google Scholar
|
|
8
|
Ben Sahra I, Laurent K, Loubat A,
Giorgetti-Peraldi S, Colosetti P, Auberger P, Tanti JF, Le
Marchand-Brustel Y and Bost F: The antidiabetic drug metformin
exerts an antitumoral effect in vitro and in vivo through a
decrease of cyclin D1 level. Oncogene. 27:3576–3586.
2008.PubMed/NCBI
|
|
9
|
Hawley SA, Gadalla AE, Olsen GS and Hardie
DG: The antidiabetic drug metformin activates the AMP-activated
protein kinase cascade via an adenine nucleotide-independent
mechanism. Diabetes. 51:2420–2425. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Towler MC and Hardie DG: AMP-activated
protein kinase in metabolic control and insulin signaling. Circ
Res. 100:328–341. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zou MH, Kirkpatrick SS, Davis BJ, Nelson
JS, Wiles WG IV, Schlattner U, Neumann D, Brownlee M, Freeman MB
and Goldman MH: Activation of the AMP-activated protein kinase by
the anti-diabetic drug metformin in vivo. Role of mitochondrial
reactive nitrogen species. J Biol Chem. 279:43940–43951. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Dowling RJ, Goodwin PJ and Stambolic V:
Understanding the benefit of metformin use in cancer treatment. BMC
Med. 6:332003.
|
|
13
|
Kahn BB, Alquier T, Carling D and Hardie
DG: AMP-activated protein kinase: ancient energy gauge provides
clues to modern understanding of metabolism. Cell Metab. 1:15–25.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Carling D: The AMP-activated protein
kinase cascade - a unifying system for energy control. Trends
Biochem Sci. 29:18–24. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stein SC, Woods A, Jones NA, Davison MD
and Carling D: The regulation of AMP-activated protein kinase by
phosphorylation. Biochem J. 345:437–443. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yun H, Lee M, Kim SS and Joohun HA:
Glucose deprivation increases mRNA stability of vascular
endothelial growth factor through activation of AMP-activated
protein kinase in DU145 prostate carcinoma. Biol Chem.
280:9963–9972. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Neurath KM, Keough MP, Mikkelsen T and
Claffey KP: AMP-dependent protein kinase alpha 2 isoform promotes
hypoxia-induced VEGF expression in human glioblastoma. Glia.
53:733–743. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lee M, Hwang JT, Lee HJ, Kang I, Kim SS
and Ha J: AMP-activated protein kinase activity is critical for
hypoxia-inducible factor-1 transcriptional activity and its target
gene expression under hypoxic conditions in DU145 cells. J Biol
Chem. 278:39653–39661. 2003. View Article : Google Scholar
|
|
19
|
Ouchi N, Shibata R and Walsh K:
AMP-activated protein kinase signaling stimulates VEGF expression
and angiogenesis in skeletal muscle. Circ Res. 96:838–846. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Nagata D, Mogi M and Walsh K:
AMP-activated protein kinase (AMPK) signalling in endothelial cells
is essential for angiogenesis in response to hypoxic stress. J Biol
Chem. 278:31000–31006. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Buzzai M, Jones RG, Amaravadi RK, Lum JJ,
DeBerardinis RJ, Zhao F, Viollet B and Thompson CB: Systemic
treatment with the antidiabetic drug metformin selectively impairs
p53-deficient tumor cell growth. Cancer Res. 67:6745–6752. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Phoenix KN, Vumbaca F and Claffey KP:
Therapeutic metformin/AMPK activation promotes the angiogenic
phenotype in the ERα negative MDA-MB-435 breast cancer model.
Breast Cancer Res Treat. 113:101–111. 2009.
|
|
23
|
Zakikhani M, Dowling R, Fantus IG,
Sonenberg N and Pollak M: Metformin is an AMP kinase-dependent
growth inhibitor for breast cancer cells. Cancer Res.
66:10269–10273. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tomimoto A, Endo H, Sugiyama M, Fujisawa
T, Hosono K, Takahashi H, Nakajima N, Nagashima Y, Wada K, Nakagama
H and Nakajima A: Metformin suppresses intestinal polyp growth in
ApcMin/+ mice. Cancer Sci. 99:2136–2141. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Luo Q, Hu D, Hu S, Yan M, Sun Z and Chen
F: In vitro and in vivo anti-tumor effect of metformin as a novel
therapeutic agent in human oral squamous cell carcinoma. BMC
Cancer. 12:5172012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Novello C, Pazzaglia L, Cingolani C, Conti
A, Quattrini I, Manara MC, Tognon M, Picci P and Benassi MS: miRNA
expression profile in human osteosarcoma: Role of miR-1 and
miR-133b in proliferation and cell cycle control. Int J Oncol.
42:667–675. 2013.PubMed/NCBI
|
|
27
|
Hidalgo M and Rowinsky EK: The
rapamycin-sensitive signal transduction pathway as a target for
cancer therapy. Oncogene. 19:6680–6686. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Collins I and Garrett MD: Targeting the
cell division cycle in cancer: CDK and cell cycle checkpoint kinase
inhibitors. Curr Opin Pharmacol. 5:366–373. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Merry C, Fu K and Wang J, Merry C, Fu K
and Wang J: Targeting the checkpoint kinase Chk1 in cancer therapy.
Cell Cycle. 9:279–283. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Alimova IN, Liu B, Fan Z, Edgerton SM,
Dillon T, Lind SE and Thor AD: Metformin inhibits breast cancer
cell growth, colony formation and induces cell cycle arrest in
vitro. Cell Cycle. 8:909–915. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Jalving M, Gietema JA, Lefrandt JD, de
Jong S, Reyners AK, Gans RO and de Vries EG: Metformin: taking away
the candy for cancer? Eur J Cancer. 46:2369–2380. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Montanini L, Lasagna L, Barili V, Jonstrup
SP, Murgia A, Pazzaglia L, Conti A, Novello C, Kjems J, Perris R
and Benassi MS: MicroRNA cloning and sequencing in osteosarcoma
cell lines: differential role of miR-93. Cell Oncol. 35:29–41.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Rocha GZ, Dias MM, Ropelle ER,
Osório-Costa F, Rossato FA, Vercesi AE, Saad MJ and Carvalheira JB:
Metformin amplifies chemotherapy-induced AMPK activation and
antitumoral growth. Clin Cancer Res. 17:3993–4005. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Motoshima H, Goldstein BJ, Igata M and
Araki E: AMPK and cell proliferation - AMPK as a therapeutic target
for atherosclerosis and cancer. J Physiol. 574:63–71. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Zhuang Y and Miskimins WK: Cell cycle
arrest in Metformin treated breast cancer cells involves activation
of AMPK, downregulation of cyclin D1, and requires
p27Kip1 or p21Cip1. J Mol Signal. 3:182008.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Eastman A: Cell cycle checkpoints and
their impact on anticancer therapeutic strategies. J Cell Biochem.
91:223–231. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tu YS, Kang XL, Zhou JG, Lv XF, Tang YB
and Guan YY: Involvement of Chk1-Cdc25A-cyclin A/CDK2 pathway in
simvastatin induced S-phase cell cycle arrest and apoptosis in
multiple myeloma cells. Eur J Pharmacol. 670:356–364. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zhao H, Watkins JI and Worms H: Disruption
of the checkpoint kinase 1/cell division cycle 25A pathway
abrogates ionizing radiation-induced S and G2 checkpoints. Proc
Natl Acad Sci USA. 99:14795–14800. 2002. View Article : Google Scholar : PubMed/NCBI
|
